CN1042329C - 用于治疗疾病的取代的环己烷衍生物 - Google Patents

用于治疗疾病的取代的环己烷衍生物 Download PDF

Info

Publication number
CN1042329C
CN1042329C CN93116663A CN93116663A CN1042329C CN 1042329 C CN1042329 C CN 1042329C CN 93116663 A CN93116663 A CN 93116663A CN 93116663 A CN93116663 A CN 93116663A CN 1042329 C CN1042329 C CN 1042329C
Authority
CN
China
Prior art keywords
compound
glucose
alkyl
solution
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN93116663A
Other languages
English (en)
Chinese (zh)
Other versions
CN1086806A (zh
Inventor
H·赫莫勒
P·史恩德乐
R·乌特兹
R·里泼尔
A·赫灵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of CN1086806A publication Critical patent/CN1086806A/zh
Application granted granted Critical
Publication of CN1042329C publication Critical patent/CN1042329C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/56Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups bound to carbon atoms of six-membered aromatic rings and carboxyl groups bound to acyclic carbon atoms of the carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/36Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/013Esters of alcohols having the esterified hydroxy group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734Ethers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55Acids; Esters
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/383Cycloaliphatic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4018Esters of cycloaliphatic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transceivers (AREA)
  • Mobile Radio Communication Systems (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
CN93116663A 1992-09-09 1993-09-08 用于治疗疾病的取代的环己烷衍生物 Expired - Fee Related CN1042329C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4230156 1992-09-09
DEP4230156.4 1992-09-09

Publications (2)

Publication Number Publication Date
CN1086806A CN1086806A (zh) 1994-05-18
CN1042329C true CN1042329C (zh) 1999-03-03

Family

ID=6467599

Family Applications (1)

Application Number Title Priority Date Filing Date
CN93116663A Expired - Fee Related CN1042329C (zh) 1992-09-09 1993-09-08 用于治疗疾病的取代的环己烷衍生物

Country Status (22)

Country Link
US (1) US5451573A (2)
EP (1) EP0587087B1 (2)
JP (1) JPH06211737A (2)
KR (1) KR100299205B1 (2)
CN (1) CN1042329C (2)
AT (1) ATE181237T1 (2)
AU (1) AU662836B2 (2)
CA (1) CA2105707A1 (2)
CZ (1) CZ284995B6 (2)
DE (1) DE59309649D1 (2)
DK (1) DK0587087T3 (2)
ES (1) ES2135429T3 (2)
FI (1) FI933902A7 (2)
GR (1) GR3030953T3 (2)
HU (1) HUT64843A (2)
IL (1) IL106935A (2)
NO (1) NO179671C (2)
PH (1) PH30278A (2)
PL (1) PL300328A1 (2)
RU (1) RU2131248C1 (2)
TW (1) TW255880B (2)
ZA (1) ZA936610B (2)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4404848A1 (de) * 1994-02-16 1995-08-17 Hoechst Ag Substituierte Cyclohexanolester, ihre Verwendung zur Behandlung von Krankheiten und pharmazeutische Präparate
DE4408082A1 (de) * 1994-03-10 1995-09-14 Hoechst Ag Substituierte Propan-Derivate, Verfahren zu ihrer Herstellung und die Anwendung der Verbindungen zur Behandlung von Krankheiten
DE4416433A1 (de) * 1994-05-10 1995-11-16 Hoechst Ag Cyclohexan-Derivate, Verfahren zu ihrer Herstellung und die Verwendung der Verbindungen zur Behandlung von Krankheiten
AR012449A1 (es) * 1997-04-18 2000-10-18 Hoechst Marion Roussell Deutschland Gmbh Kodaistatinas a, b, c y d, proceso para su produccion, y su uso.
JP4810558B2 (ja) * 1997-08-08 2011-11-09 江崎グリコ株式会社 リン酸化糖およびその製造方法
DE19740080A1 (de) * 1997-09-12 1999-03-18 Hoechst Marion Roussel De Gmbh Neue Phthalaldehyd-Derivate, Verfahren zu deren Herstellung und deren Verwendung
EP1090136B1 (en) * 1998-06-24 2006-05-31 Sanofi-Aventis Deutschland GmbH Mumbaistatin, a process for its production and its use as a pharmaceutical
SK287428B6 (sk) * 1999-10-25 2010-09-07 Sanofi-Aventis Deutschland Gmbh Aromatické diketoderiváty, spôsob ich prípravy a farmaceutická kompozícia, ktorá ich obsahuje
PE20021091A1 (es) * 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
PL2522663T3 (pl) 2004-06-03 2015-08-31 Eisai R&D Man Co Ltd Produkty pośrednie do otrzymywania halichondryny B
ZA200700755B (en) * 2004-07-26 2009-05-27 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes
CN108948039B (zh) 2007-10-03 2021-12-31 卫材R&D管理有限公司 用于合成软海绵素b类似物的中间体和方法
CN105801599A (zh) 2008-04-04 2016-07-27 卫材R&D管理有限公司 软海绵素b类似物
US20100112098A1 (en) * 2008-10-31 2010-05-06 Naturex, S.A. Effects of a decaffeinated green coffee extract on body weight control by regulation of glucose metabolism
CN102803254B (zh) 2010-01-26 2016-09-14 卫材R&D管理有限公司 用于软海绵素b类似物合成的呋喃并[3,2-b]吡喃衍生物
CN105683198B (zh) 2013-11-04 2019-03-12 卫材R&D管理有限公司 软海绵素b的类似物合成中有用的大环化反应和中间体
HUE043088T2 (hu) 2013-12-06 2019-08-28 Eisai R&D Man Co Ltd Halikondrin B analógok szintézisében alkalmazható eljárások
RU2020141025A (ru) 2015-05-07 2020-12-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Реакции макроциклизации и промежуточные соединения и другие фрагменты, полезные в синтезе макролидов галихондринов
US10676481B2 (en) 2016-02-12 2020-06-09 Eisai R&D Management Co., Ltd. Intermediates in the synthesis of eribulin and related methods of synthesis
SG11201811671XA (en) 2016-06-30 2019-01-30 Eisai R&D Man Co Ltd Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof
KR20250057138A (ko) 2018-01-03 2025-04-28 에자이 알앤드디 매니지먼트 가부시키가이샤 할리콘드린 마크롤리드 및 그의 유사체의 합성에 유용한 프린스 반응 및 화합물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0163270A2 (en) * 1984-05-23 1985-12-04 Green Cross Corporation A lipoxygenase inhibitor
WO1987004619A1 (fr) * 1986-02-06 1987-08-13 Code Kaffee-Handelsgesellschaft Mbh Emploi de tanins et/ou d'acide chlorogene, ainsi que stimulants, aliments et/ou medicaments avec addition de tanin et/ou d'acide chlorogene

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60192555A (ja) * 1984-03-13 1985-10-01 Osaka Chem Lab 抗アレルギ−食品
JPS60243016A (ja) * 1984-05-17 1985-12-03 Tsumura Juntendo Inc 抗インフルエンザウイルス剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0163270A2 (en) * 1984-05-23 1985-12-04 Green Cross Corporation A lipoxygenase inhibitor
WO1987004619A1 (fr) * 1986-02-06 1987-08-13 Code Kaffee-Handelsgesellschaft Mbh Emploi de tanins et/ou d'acide chlorogene, ainsi que stimulants, aliments et/ou medicaments avec addition de tanin et/ou d'acide chlorogene

Also Published As

Publication number Publication date
CN1086806A (zh) 1994-05-18
JPH06211737A (ja) 1994-08-02
NO179671B (no) 1996-08-19
AU4617093A (en) 1994-03-17
HK1011934A1 (en) 1999-07-23
TW255880B (2) 1995-09-01
CZ186793A3 (en) 1994-03-16
KR940006580A (ko) 1994-04-25
NO933201D0 (no) 1993-09-08
RU2131248C1 (ru) 1999-06-10
ZA936610B (en) 1994-03-28
KR100299205B1 (ko) 2001-11-22
ATE181237T1 (de) 1999-07-15
GR3030953T3 (en) 1999-11-30
FI933902L (fi) 1994-03-10
NO179671C (no) 1996-11-27
EP0587087B1 (de) 1999-06-16
HU9302527D0 (en) 1993-11-29
DK0587087T3 (da) 1999-12-06
PL300328A1 (en) 1994-03-21
FI933902A0 (fi) 1993-09-07
DE59309649D1 (de) 1999-07-22
US5451573A (en) 1995-09-19
CA2105707A1 (en) 1994-03-10
IL106935A (en) 1997-07-13
PH30278A (en) 1997-02-20
AU662836B2 (en) 1995-09-14
ES2135429T3 (es) 1999-11-01
EP0587087A1 (de) 1994-03-16
HUT64843A (en) 1994-03-28
CZ284995B6 (cs) 1999-04-14
IL106935A0 (en) 1993-12-28
NO933201L (no) 1994-03-10
FI933902A7 (fi) 1994-03-10

Similar Documents

Publication Publication Date Title
CN1086806A (zh) 用于治疗疾病的取代的环己烷衍生物
RU2444518C2 (ru) ПРОИЗВОДНОЕ ТИАЗОЛА КАК PPARδ ЛИГАНД И ФАРМАЦЕВТИЧЕСКИЙ, КОСМЕТИЧЕСКИЙ И ДИЕТИЧЕСКИЙ ПИЩЕВОЙ ПРОДУКТ, СОДЕРЖАЩИЙ ЕГО
CH636606A5 (de) Verfahren zur herstellung neuer prostensaeuren und -alkylestern.
EP1453840A1 (fr) Phosphonates utiles comme modulateurs de l'activite des lymphocytes t-gamma-9-delta-2
DE1643122A1 (de) Verfahren zur Herstellung von Verbindungen,die sich von Prostaglandin ableiten,sowie von Verbindungen mit prostaglandinaehnlicher Aktivitaet
US6410780B1 (en) C11 oxymyl and hydroxylamino prostaglandins useful as medicaments
Yamamoto et al. Structural analysis of 5, 6-dideoxy-5-C-[(R and S)-phenylphosphinyl]-L-ido-hexopyranoses by 400-MHz proton nuclear magnetic resonance
CA2036920A1 (fr) Sels de metaux alcalinoterreux d'oxa-polyacides leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP3522790B2 (ja) H3−レセプター刺激薬
US5175179A (en) Method for treating hypertension
JP3479985B2 (ja) 血小板凝集阻害剤
CN1098258C (zh) 异香豆素衍生物及其在医药上的应用
US3726983A (en) Pharmaceutical compositions comprising tetrahydropyran-2{40 -yl prostaglandin ethers
JPH05117230A (ja) プロスタグランジン誘導体
JPH08208637A (ja) プロスタグランジンi型化合物、その中間体、それらの製造方法及び血小板凝集抑制剤
JP3534433B2 (ja) 血小板凝集阻害剤
US3920827A (en) Pharmaceutical compositions containing therapeutic 5',6'-dihydro-2h-pyran-4'-yloxy prostaglandins
JPH05294924A (ja) プロスタグランジンe1類縁体
JP3043118B2 (ja) 共役γ−ヒドロキシブテノライド化合物およびこれを有効成分とする制ガン剤
JP3316050B2 (ja) プロスタグランジンe1類縁体
BE863116A (fr) Nouveaux derives 17-aza-pgf2alpha, procede permettant de les preparer et compositions pharmaceutiques qui les contiennent.
HUT63401A (en) Process for producing prostagladin i2 derivatives and pharmaceutical compositions comprising such active ingredient
JPWO1992018473A1 (ja) プロスタグランジンe↓1類縁体
JPH06107626A (ja) プロスタグランジン誘導体
CZ20003447A3 (cs) Cll-Oximylová a hydroxylaminová prostaglandinová sloučenina a její použití

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee